Exelixis, Inc. (NASDAQ:EXEL) announced the presentation of new data from clinical trials of cobimetinib in combination with other therapies to treat forms of advanced …
As Exelixis, Inc.’s (NASDAQ:EXEL) “impressive launch continues” for its pipeline drug Cabometyx, approved to treat second-line advanced renal cell carcinoma (RCC), the most …
Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the third quarter of 2016 and provided an update on progress toward delivering upon its key 2016 …
Cowen’s biotech team weighs in with upbeat perspectives on biotech firms Gilead Sciences, Inc. (NASDAQ:GILD), Exelixis Inc.
Illumina, Inc. Illumina, Inc.
In a research report published Monday, Cowen analyst Eric Schmidt reiterated an Outperform rating on shares Exelixis, Inc. (NASDAQ:EXEL), after the drug maker announced detailed results …
Exelixis, Inc. (NASDAQ:EXEL) announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) …
Exelixis, Inc. (NASDAQ:EXEL) announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.
Leerink top analyst Michael Schmidt provides insight on shares of Exelixis, Inc (NASDAQ:EXEL) after hosting the 2016 Leerink Partners Immuno-Oncology Roundtable Conference in …
Exelixis, Inc. (NASDAQ:EXEL) announced that its partner Daiichi Sankyo Company, Limited(hereafter, Daiichi Sankyo) has initiated a phase 3 pivotal trial to evaluate CS-3150 (esaxerenone …
